Wockhardt, the global pharmaceutical and biotechnology major announced on Monday that it has entered into an agreement with the UK Government to fill-finish COVID-19 vaccines. The manufacturing will be done at CP Pharmaceuticals, a subsidiary of Wockhardt based in Wrexham, North Wales.
About Wockhardt
Wockhardt is a global pharmaceutical and biotech organisation headquartered in Mumbai. It brings affordable, high-quality medicines to market. In the UK, it is one of the largest suppliers into the NHS for over 20 years, has had a presence in Wrexham for over two decades and employs over 400 people at its 612,000 square feet high-tech manufacturing facility.
What is the Partnership About?
According to the press-release ” As per the terms of the agreement the company has reserved manufacturing capacity to allow for the supply of multiple vaccines to the UK Government in its fight against COVID19, including AZD1222, the vaccine co-invented by the University of Oxford and its spinout company, Vaccitech and licensed by AstraZeneca.”
How did the market react?
Wockhardt had a gap-up opening on 3rd August after the announcement on tie-up with the UK government. The scrip hit the 10% upper-circuit for two days in a row.
You may read the official press release over here.
